Immunedesign Security Rating

Immune Design is a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The company is focused on oncology and have engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells, or CTLs, to fight cancer. Its immuno-oncology product candidates are being developed in two separate approaches: one that targets specific antigens and/or epitopes; and an alternative approach that leverages the endogenous antigens found in the tumor microenvironment via intratumoral immunization. The specific antigen approach uses selected antigens that are also present in the patient’s tumor so that the immune system will be educated to recognize the tumor antigen and kill tumor cells expressing the antigen.